Renovo Concepts

Renovo Concepts is pioneering a new therapeutic approach for traumatic injuries with its Mechanical Tissue Resuscitation (MTR®) platform. Founded by the inventors of the widely adopted V.A.C. negative pressure wound therapy, the company is initially targeting traumatic brain injury (TBI), a condition with significant unmet need and little innovation in over a century. The company is currently conducting first-in-human clinical trials, positioning its lead program at an early clinical stage with potential applications in other organ systems like the heart and spinal cord.

Mechanical Tissue Resuscitation (MTR®): A device-based platform applying controlled sub-atmospheric pressure to the site of injury to actively remove excess fluid, reduce edema, improve perfusion, and mitigate secondary tissue damage.

The field for active TBI therapies is relatively uncrowded due to historical lack of innovation. Renovo's main competition is the entrenched standard of care (surgery and pharmacologic management). Other companies may be exploring neuroprotective drugs or other devices, but MTR®'s mechanical approach and the founders' proven track record with negative pressure therapy provide a unique competitive position.